NCT06941415View on ClinicalTrials.gov

Bumetanide vs. Furosemide in Cirrhosis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 31, 2027

Conditions
Cirrhosis
Interventions
DRUG

Bumetanide

Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders

DRUG

Furosemide

Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders

Trial Locations (1)

84132

University of Utah Hospital, Salt Lake City

All Listed Sponsors
lead

Stacy Johnson

OTHER